MX2017016517A - Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. - Google Patents

Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.

Info

Publication number
MX2017016517A
MX2017016517A MX2017016517A MX2017016517A MX2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A MX 2017016517 A MX2017016517 A MX 2017016517A
Authority
MX
Mexico
Prior art keywords
methods
storage stable
eye
refractive errors
treatment
Prior art date
Application number
MX2017016517A
Other languages
English (en)
Inventor
Horn Gerald
NORDAN Lee
Original Assignee
Presbyopia Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/742,921 external-priority patent/US9314427B2/en
Priority claimed from US14/742,903 external-priority patent/US9320709B2/en
Application filed by Presbyopia Therapies Llc filed Critical Presbyopia Therapies Llc
Publication of MX2017016517A publication Critical patent/MX2017016517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención provee composiciones y métodos para lograr aceclidina estable al almacenamiento; las composiciones comprenden preferiblemente aceclidina, un agente ciclopléjico, un tensoactivo, un ajustador de la tonicidad y opcionalmente un potenciador de la viscosidad y un antioxidante; la invención proporciona además métodos para tratar errores de refracción del ojo con una composición de acetilidina estable al almacenamiento.
MX2017016517A 2015-06-18 2016-06-09 Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo. MX2017016517A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/742,921 US9314427B2 (en) 2013-08-28 2015-06-18 Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US14/742,903 US9320709B2 (en) 2013-08-28 2015-06-18 Storage stable compositions and methods for the treatment of refractive errors of the eye
PCT/US2016/036687 WO2016205068A1 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye

Publications (1)

Publication Number Publication Date
MX2017016517A true MX2017016517A (es) 2018-05-28

Family

ID=57545598

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016518A MX2017016518A (es) 2015-06-18 2016-06-09 Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
MX2017016517A MX2017016517A (es) 2015-06-18 2016-06-09 Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016518A MX2017016518A (es) 2015-06-18 2016-06-09 Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.

Country Status (9)

Country Link
EP (3) EP3310336A4 (es)
JP (3) JP6838712B2 (es)
KR (4) KR102598047B1 (es)
CN (3) CN107847492B (es)
AU (2) AU2016280616B2 (es)
CA (2) CA2987787C (es)
HK (1) HK1254338A1 (es)
MX (2) MX2017016518A (es)
WO (2) WO2016205069A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017016518A (es) * 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
EA201992234A1 (ru) * 2017-03-23 2020-02-05 Сингапур Хелт Сервисиз Пте Лтд Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента
PL3548000T3 (pl) 2017-05-11 2022-01-17 Vyluma Inc. Kompozycja farmaceutyczna atropiny
AU2019357979A1 (en) * 2018-10-10 2021-04-29 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
KR20230131822A (ko) * 2020-10-13 2023-09-14 렌즈 테라퓨틱스 인코포레이티드 저장 안정성 안약을 위한 조성물 및 방법
CA3195784A1 (en) * 2020-11-02 2022-05-05 Rhett Mead SCHIFFMAN Degradant compound in a medicament
EP4308080A1 (en) * 2021-03-16 2024-01-24 Vyluma Inc. Multi-dose container for ophthalmic compositions
KR20220154509A (ko) 2021-05-13 2022-11-22 전연우 복용 시간을 알려주고 편하게 약을 꺼낼 수 있는 약통
TW202333700A (zh) * 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法
KR20230126461A (ko) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물
KR20230126522A (ko) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 고분자 히알루론산의 구조체, 이의 제조방법 및 이를 포함하는 점안 조성물
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6353022B1 (en) * 1999-11-09 2002-03-05 Alcon Universal Ltd. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US7830573B2 (en) 2005-11-03 2010-11-09 Stamper Technologies, Inc. Method and system for producing multiple images in a single image plane using diffraction
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
WO2009090495A2 (en) * 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
CA2849192C (en) * 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
DE102011121770A1 (de) 2011-12-21 2013-06-27 Oerlikon Trading Ag, Trübbach Homogenes HIPIMS-Beschichtungsverfahren
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US9573840B2 (en) * 2013-08-27 2017-02-21 Corning Incorporated Antimony-free glass, antimony-free frit and a glass package that is hermetically sealed with the frit
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
MX2017016518A (es) * 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.

Also Published As

Publication number Publication date
JP2018517738A (ja) 2018-07-05
EP4385521A2 (en) 2024-06-19
WO2016205069A1 (en) 2016-12-22
BR112017025722A2 (pt) 2018-08-07
JP6838712B2 (ja) 2021-03-03
KR20180014824A (ko) 2018-02-09
JP2021035954A (ja) 2021-03-04
MX2017016518A (es) 2018-05-28
KR102598047B1 (ko) 2023-11-06
KR102667598B1 (ko) 2024-05-20
EP3310336A4 (en) 2018-12-05
WO2016205068A1 (en) 2016-12-22
AU2016280615B2 (en) 2020-10-01
KR20180014825A (ko) 2018-02-09
AU2016280616B2 (en) 2020-10-22
CA2987787A1 (en) 2016-12-22
CN107847492A (zh) 2018-03-27
KR20230156161A (ko) 2023-11-13
JP7026189B2 (ja) 2022-02-25
JP2018517740A (ja) 2018-07-05
HK1254338A1 (zh) 2019-07-19
KR20230085217A (ko) 2023-06-13
AU2016280616A1 (en) 2017-12-14
JP6835747B2 (ja) 2021-02-24
EP3310336A1 (en) 2018-04-25
CN116808032A (zh) 2023-09-29
AU2016280615A1 (en) 2017-12-14
BR112017025726A2 (pt) 2018-08-14
CA2987783A1 (en) 2016-12-22
CN107847492B (zh) 2021-05-25
CN107920984A (zh) 2018-04-17
EP3310356A4 (en) 2018-12-05
EP3310356A1 (en) 2018-04-25
CA2987787C (en) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020002922A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
IL273300A (en) High dose valbenazine formulation and related preparations, methods and kits
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2018011300A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018003301A (es) Inhibidores de pcna.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2017017119A (es) Formulacion de alta concentracion.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2017013879A (es) Composiciones que comprenden anakinra.

Legal Events

Date Code Title Description
FG Grant or registration